A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the agency's website, as the Trump administration halts DEI initiatives.

Research that has not yet been peer-reviewed shows the newest blood test is more than 80% accurate in detecting colon cancer in people who had the disease. The test is 90% accurate in ruling out cancer in healthy adults, according to the study published Monday in the Journal of Clinical Oncology.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety of tumors.

As part of the second Trump Administration's diversity witchhunt, cancer research and other crucial projects have been paused indefinitely. As Mother Jones reports, this administration's pushback against diversity,

Already banned in cosmetics and topical medicines since 1990, the Food and Drug Administration announced on Wednesday that Red 3 will now be banned in food, drink, and ingestible medications.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday.

Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib.

Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the US and European Union for some breast cancer patients whose cancer spread after receiving treatment, or whose disease returned after surgery.

Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S. is beginning to phase it out of foods and drugs.

Studies going back decades have shown a potential link between artificial food dyes and attention deficit hyperactivity disorder symptoms in kids.

The U.S. Food and Drug Administration wants to put nutrition information front and center on food products to give consumers an easier way to identify nutrients linked to chronic diseases. The FDA announced its plans to push for a rule that would require food manufacturers to include a front-of-package nutrition label on most packaged food products.

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.